High Liner buying Mrs. Paul's and Van de Kamp's brands from Conagra for US$55M
High Liner Foods currently co-manufactures products for Mrs. Paul's and Van de Kamp's brands at its U.S-based operations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
3 hours ago
- Winnipeg Free Press
Costco gets go-ahead to take next step toward West St. Paul store
Costco Wholesale Corp. has received the green light to move ahead with a new 162,000-square-foot store in the Rural Municipality of West St. Paul following a June public hearing. It comes amid steady growth in the area. 'It's a really good location,' said West St. Paul Mayor Peter Truijen. A construction timeline wasn't available Monday. The location will be Costco's first in north Winnipeg. MIKE SUDOMA / FREE PRESS FILES A new Costco location is going ahead in West St. Paul. A seasonal garden centre, eatery, auto service station and more than 1,000 parking stalls will be part of the development. The U.S.-based multinational retailer has claimed a 21-acre site south of the Perimeter Highway and west of Main Street. It's part of Meadowlands, one of two developments under construction in West St. Paul. Meadowlands — spanning 380 acres — will include 2,036 homes once completed, according to Winnipeg-based developer United Equities Group. Exemplar Developments, another Winnipeg company, is also developing the land. Demand has been 'extremely strong,' said Warren Greenspoon, chief executive of United Equities Group. Construction on Parkview Pointe, on the other side of the Perimeter, is also ongoing. West St. Paul has logged an average of 240 houses built per year since 2022, Truijen said, adding he is expecting another 300 to be constructed this year. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. Two new developments — aside from Meadowlands and Parkview Pointe — are also in the works, Truijen said. McDonald's and Costco are the first brands announced for Meadowlands. Winnipeg currently has three Costcos: on Regent Avenue, McGillivray Boulevard and St. James Street. Another store, at 4077 Portage Ave., is currently being built. — Free Press staff
Global News
10 hours ago
- Global News
Bid by 23andMe's former CEO to buy company given greenlight by court
Anne Wojcicki's bid to buy 23andMe, the genetic testing company she cofounded nearly 20 years ago, has received the court greenlight. That means Wojcicki's nonprofit TTAM Research Institute will purchase 'substantially all' of San Francisco-based 23andMe's assets for US$305 million. The transaction — which arrives more than three months after 23andMe filed for Chapter 11 bankruptcy — is set to officially close in the coming weeks. 'I am thrilled that TTAM will be able to build on the mission of 23andMe to help people access, understand and benefit from the human genome,' Wojcicki said in a statement Monday — later adding that, 'the future of health care belongs to all of us.' The sale, which was approved by U.S. Bankruptcy Judge Brian C. Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe's assets for US$256 million in May. But Wojcicki's nonprofit later topped that offer, winning the final round of bidding held last month. Story continues below advertisement Under the deal, TTAM will acquire 23andMe's signature 'Personal Genome Service' provided through the company's saliva-based DNA testing kits — as well as research operations and its Lemonaid Health subsidiary, a telehealth services provider that 23andMe previously planned to wind down. Wojcicki had worked to take 23andMe private for some time. With the company struggling to find a profitable business model since going public in 2021, she's maintained that it would operate better outside market pressures. But that endeavor proved to be tumultuous — notably in September of last year, when all of 23andMe's independent directors resigned from its board citing a 'clear' difference of opinion with Wojcicki on the company's future following drawn-out negotiations. Get breaking National news For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen. Sign up for breaking National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Leading up to 23andMe's March bankruptcy filing, subsequent efforts from Wojcicki to acquire the company were unsuccessful. And when 23andMe filed for Chapter 11 in late March, Wojcicki resigned as CEO — noting at the time that she was stepping down to be 'in the best position' as an independent bidder. 1:19 23andMe lacked strong data protection allowing for breach: Canada's privacy head Now that Wojcicki's nonprofit will acquire 23andMe, it's unclear whether the co-founder will step back into the CEO seat. But despite stepping down from the top post months ago, Wojcicki has remained on the company's board throughout the bankruptcy process. Story continues below advertisement Beyond financial strains leading up to 23andMe's bankruptcy, privacy concerns related to customers' genetic information also emerged — dating back to even before the bankruptcy process with a 2023 data breach. But concern what new ownership could mean for 23andMe users' personal data has bubbled up in recent months. The genetic testing business had about 13 million customers at the time of its sale hearing, court documents note. In June, 27 states and the District of Columbia filed a lawsuit seeking to block the sale of personal genetic data by 23andMe without customer consent. And in a memorandum opinion outlining his approval 23andMe's sale to TTAM on Friday, Walsh acknowledged these states' objections to the acquisition — but that noted many had since been resolved. Still, California, Kentucky, Tennessee, Texas, and Utah 'remain actively opposed to the sale.' In a statement to Politico on Monday, California Attorney General Rob Bonta's office maintained that 23andMe's sale 'does not comply' with genetic privacy law in the state — and said it was 'disappointed' with the court's approval, adding that it was evaluating next steps. The Associated Press reached out to Bonta's office and 23andMe for further comments on Tuesday. When announcing its intended sale to Wojcicki's nonprofit last month, 23andMe confirmed that TTAM 'has affirmed its commitment' to comply with the company privacy policies and applicable law. That means TTAM will honor existing policies around consumer data, the company said, which includes allowing users to delete their data and 'opt out' of research. Story continues below advertisement All customers will be emailed at least two business days before the acquisition closes — with details on TTAM's privacy commitments and instructions on how to delete data or opt out of research, 23andMe said. The company added that TTAM will offer customers two years of Experian identity theft monitoring at no cost. 23andMe reiterated those privacy policies on Monday. And Wojcicki added that, 'Core to my beliefs is that individuals should be empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish.'
Winnipeg Free Press
10 hours ago
- Winnipeg Free Press
Anne Wojcicki's nonprofit gets court approval to buy 23andMe for $305 million
NEW YORK (AP) — Anne Wojcicki's bid to buy 23andMe, the genetic testing company she cofounded nearly 20 years ago, has received the court greenlight. That means Wojcicki's nonprofit TTAM Research Institute will purchase 'substantially all' of San Francisco-based 23andMe's assets for $305 million. The transaction — which arrives more than three months after 23andMe filed for Chapter 11 bankruptcy — is set to officially close in the coming weeks. 'I am thrilled that TTAM will be able to build on the mission of 23andMe to help people access, understand and benefit from the human genome,' Wojcicki said in a statement Monday — later adding that, 'the future of health care belongs to all of us.' The sale, which was approved by U.S. Bankruptcy Judge Brian C. Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe's assets for $256 million in May. But Wojcicki's nonprofit later topped that offer, winning the final round of bidding held last month. Under the deal, TTAM will acquire 23andMe's signature 'Personal Genome Service' provided through the company's saliva-based DNA testing kits — as well as research operations and its Lemonaid Health subsidiary, a telehealth services provider that 23andMe previously planned to wind down. Wojcicki had worked to take 23andMe private for some time. With the company struggling to find a profitable business model since going public in 2021, she's maintained that it would operate better outside market pressures. But that endeavor proved to be tumultuous — notably in September of last year, when all of 23andMe's independent directors resigned from its board citing a 'clear' difference of opinion with Wojcicki on the company's future following drawn-out negotiations. Leading up to 23andMe's March bankruptcy filing, subsequent efforts from Wojcicki to acquire the company were unsuccessful. And when 23andMe filed for Chapter 11 in late March, Wojcicki resigned as CEO — noting at the time that she was stepping down to be 'in the best position' as an independent bidder. Now that Wojcicki's nonprofit will acquire 23andMe, it's unclear whether the co-founder will step back into the CEO seat. But despite stepping down from the top post months ago, Wojcicki has remained on the company's board throughout the bankruptcy process. Beyond financial strains leading up to 23andMe's bankruptcy, privacy concerns related to customers' genetic information also emerged — dating back to even before the bankruptcy process with a 2023 data breach. But concern what new ownership could mean for 23andMe users' personal data has bubbled up in recent months. The genetic testing business had about 13 million customers at the time of its sale hearing, court documents note. In June, 27 states and the District of Columbia filed a lawsuit seeking to block the sale of personal genetic data by 23andMe without customer consent. And in a memorandum opinion outlining his approval 23andMe's sale to TTAM on Friday, Walsh acknowledged these states' objections to the acquisition — but that noted many had since been resolved. Still, California, Kentucky, Tennessee, Texas, and Utah 'remain actively opposed to the sale.' Monday Mornings The latest local business news and a lookahead to the coming week. In a statement to Politico on Monday, California Attorney General Rob Bonta's office maintained that 23andMe's sale 'does not comply' with genetic privacy law in the state — and said it was 'disappointed' with the court's approval, adding that it was evaluating next steps. The Associated Press reached out to Bonta's office and 23andMe for further comments on Tuesday. When announcing its intended sale to Wojcicki's nonprofit last month, 23andMe confirmed that TTAM 'has affirmed its commitment' to comply with the company privacy policies and applicable law. That means TTAM will honor existing policies around consumer data, the company said, which includes allowing users to delete their data and 'opt out' of research. All customers will be emailed at least two business days before the acquisition closes — with details on TTAM's privacy commitments and instructions on how to delete data or opt out of research, 23andMe said. The company added that TTAM will offer customers two years of Experian identity theft monitoring at no cost. 23andMe reiterated those privacy policies on Monday. And Wojcicki added that, 'Core to my beliefs is that individuals should be empowered to have choice and transparency with respect to their genetic data and have the opportunity to continue to learn about their ancestry and health risks as they wish.'
